Challenges in the diagnosis and treatment of pulmonary arterial hypertension.
Affiliation
Pulmonary Vascular Diseases and Heart Failure Clinic, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. # National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland.Issue Date
2012-12-01
Metadata
Show full item recordCitation
Challenges in the diagnosis and treatment of pulmonary arterial hypertension. 2012, 21 (126):313-20 Eur Respir RevJournal
European respiratory review : an official journal of the European Respiratory SocietyURI
http://hdl.handle.net/10147/255061http://err.ersjournals.com/cgi/content/full/21/126/313?ijkey=IfBwQvmSo9332&keytype=ref&siteid=ersjnls
DOI
10.1183/09059180.00005412PubMed ID
23204119Abstract
Advances in the diagnosis and management of pulmonary arterial hypertension (PAH) have resulted in significant improvements in outcomes for patients with this devastating and progressive disease. However, because of the non-specific nature of its symptoms, and the low level of suspicion among clinicians, prompt and accurate diagnosis of PAH as a rare disease remains a challenge. This article explains some of the issues that need to be addressed when faced with a patient with suspected PAH and describes how noninvasive and invasive techniques can be used effectively to ensure an accurate diagnosis. The availability of PAH-specific therapy means that once diagnosed, patients have a much greater chance of survival than they would have had in the past. However, despite improved survival, mortality is still high and, therefore, there is still room for improvement. It is currently recommended that patients with an inadequate clinical response to treatment receive sequential combination therapy; however, supportive data are still scarce. Although there is no clear explanation, these findings may be explained by the design and end-points chosen in clinical trials, the changing population of PAH and a need to improve the management strategy in this disease. Indeed, there is a clear need for randomised controlled studies that investigate whether adopting individualised treatment strategies, including upfront combination therapy, could help to optimise long-term management of patients with PAH.Item Type
ArticleLanguage
enISSN
1600-0617ae974a485f413a2113503eed53cd6c53
10.1183/09059180.00005412
Scopus Count
Collections
Related articles
- Pulmonary Arterial Hypertension: Diagnosis and Treatment.
- Authors: Barnett CF, Alvarez P, Park MH
- Issue date: 2016 Aug
- Screening for pulmonary arterial hypertension in patients with scleroderma--a New Zealand perspective.
- Authors: Ghosh SK, Corkill MM, Hart HH, Ng KP
- Issue date: 2014 Aug 15
- Pulmonary arterial hypertension: a current review of pharmacological management.
- Authors: Sahni S, Ojrzanowski M, Majewski S, Talwar A
- Issue date: 2016
- Pulmonary arterial hypertension.
- Authors: Traiger GL
- Issue date: 2007 Jan-Mar
- Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
- Authors: Kozlik-Feldmann R, Hansmann G, Bonnet D, Schranz D, Apitz C, Michel-Behnke I
- Issue date: 2016 May